REG - N4 Pharma PLC - Director Appointment

N4 PharmaAnnouncement

09/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240909:nRSI2998Da&default-theme=true

RNS Number : 2998D  N4 Pharma PLC  09 September 2024

9 September 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

 

Director Appointment

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments, gene therapy and
vaccines, is pleased to announce the appointment of Dr Michael Palfreyman as
an independent Non-Executive Director of the Company with immediate effect.

 

Dr Palfreyman has more than four decades of successful drug discovery and
development experience in several therapeutic areas with two major
pharmaceutical companies (Marrion Meryl Dow, now Sanofi, and Beecham
Pharmaceuticals, now GSK) and has co-founded and developed several
biotechnology companies including, among others, Co-Founder of Scriptgen
(Anadys) Pharmaceuticals which was sold to Roche in 2011 for US$230 million
and Co-Founder and CSO of Amorsa Therapeutics, Inc. developing novel
treatments for depression and pain where he oversaw a successful US$180
million exit.

 

Dr Palfreyman currently advises Cybin Inc. listed on the New York Exchange
(NYSE: CYBN) and was Chairman and COO to Adelia Therapeutics Inc. that merged
in 2020 to form the current Cybin Inc. Dr Palfreyman has served on various
scientific advisory boards and has been an adviser to The Forsyth Institute,
Stanford Research Institute, NeuroNascent, MAK Scientific and Jasco
Pharmaceuticals.

 

Dr Palfreyman is an Emeritus Fellow of the American College of
Neuropsychopharmacology. He is co-inventor on 55 issued US and European
patents, multiple pending patents, and has co-authored over 150 scientific
articles and book chapters.

 

Dr Palfreyman joins the Company's remuneration and audit committees.

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented: "We are
delighted to welcome someone of Mike's calibre to the board of N4 Pharma.
His successful career in drug discovery and development is sure to be a great
asset to the Company, as will his industry connections and contacts across the
US which we are confident will help in our drive to commercialise Nuvec.®"

 

Mike Palfreyman, commented:  "As a scientist and entrepreneur who works at
the cutting edge of therapeutic development, N4 Pharma's unique delivery
technologies clearly show the potential to advance the clinical applications
of several promising therapeutics, and I am excited by the opportunity to join
the board of this exceptional company."

 

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies in relation to Dr Michael Gavin
Palfreyman, aged 78 :

 

 

 Current Directorships/Partnerships                    Past Directorships/Partnerships (within 5 years)
 Palfreyman BioPharm Advisors, LLC                     Adelia Therapeutics, Inc.

 AlNivo Therapeutics, Inc.

 

 

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                          Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub            Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 To find out more, visit                                      https://investors.n4pharma.com/link/lejRpe
                                                              (https://investors.n4pharma.com/link/lejRpe)
 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

 

 

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary Nanogenics.

 

N4 Pharma's business model is to partner with companies developing products in
these fields to use Nuvec® or Liptide® as the delivery vehicle for these
products. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFESASIRIIS